首页> 外文OA文献 >108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes

【2h】

108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes

机译：108P Pembrolizumab在预处理的晚期非小细胞肺癌（NSCLC）患者（PTS）：血基生物标志物对存活结果的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A. Ortega Franco; R. Tay; H. Raja; C.J. Ackermann; M. Carter; C. Lindsay; S. Hughes; L. Cove-Smith; P. Taylor; Y. Summers; F.H. Blackhall; R. Califano;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database [J] . Naqash Abdul Rafeh, Stroud Chipman Robert Geoffrey, Butt Muhammad Umer, Acta oncologica. . 2018,第6期

机译：用反向细胞死亡1治疗治疗的晚期非小细胞肺癌外周血炎性生物标志物的整体存活共同关系：单一制度数据库的结果
2. Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) [J] . Sequist L., Wu Y., Schuler M., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：阿法替尼与化学疗法对晚期非小细胞肺癌（NSCLC）患者的总生存率（OS）共有（Del19 / L858R）表皮生长因子受体突变（EGFR Mut）：LUX-Lung 3（LL3）的结果）和LUX-Lung 6（LL6）
3. 83?The prognostic significance of peripheral blood biomarkers in patients with advanced non-small cell lung cancer treated with pembrolizumab: a clinical study [J] . Kira MacDougall, Muhammad Niazi, Jeff Hosry, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：83？用Pembolizumab治疗的晚期非小细胞肺癌患者外周血生物标志物的预后意义：临床研究
4. Does Sex Make a Difference in Survival of Patients Undergoing Resection for Early Stage Non-Small Cell Lung Cancer (NSCLC)? [C] . Steven J.Jubelirer, Nicole L.Varela, Christine A.Welch, 21st international conference on screening for lung cancer . 2009

机译：性别对早期非小细胞肺癌（NSCLC）切除患者的生存率有影响吗？
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab [O] . Edoardo Lenci, Luca Cantini, Federica Pecci, 2021

机译：古斯塔韦鲁西免疫（Grim）-core变异是用第一线彭布罗卢比的晚期非小细胞肺癌（NSCLC）患者的早期治疗生物标志物
7. O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response [O] . J. Brahmer, L. Horn, B. Hossein, 2019

机译：o.02具有前期治疗的晚期非小细胞肺癌的PTS（NSCLC）的Nivolumab（Nivo）的长期存活结果：早期疾病控制和反应的影响

108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes

著录项

引文网络

相似文献

相关主题

期刊订阅